Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Arcus Biosciences, Inc. (RCUS : NYSE)
 
 • Company Description   
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.

Number of Employees: 627

 
 • Price / Volume Information   
Yesterday's Closing Price: $19.72 Daily Weekly Monthly
20 Day Moving Average: 1,442,582 shares
Shares Outstanding: 107.97 (millions)
Market Capitalization: $2,129.25 (millions)
Beta: 0.77
52 Week High: $22.11
52 Week Low: $6.50
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 47.49% 44.80%
12 Week 112.50% 96.96%
Year To Date 32.44% 16.90%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3928 Point Eden Way
-
Hayward,CA 94545
USA		 ph: 510-694-6200
fax: -		 investorinfo@arcusbio.com http://www.arcusbio.com
 
 • General Corporate Information   
Officers
Terry Rosen - Chief Executive Officer
Robert C. Goeltz II - Chief Financial Officer
Kathryn Falberg - Director
Linda Higgins - Director
Yasunori Kaneko - Director

Peer Information
Arcus Biosciences, Inc. (CORR.)
Arcus Biosciences, Inc. (RSPI)
Arcus Biosciences, Inc. (CGXP)
Arcus Biosciences, Inc. (BGEN)
Arcus Biosciences, Inc. (GTBP)
Arcus Biosciences, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03969F109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 02/24/26
Share - Related Items
Shares Outstanding: 107.97
Most Recent Split Date: (:1)
Beta: 0.77
Market Capitalization: $2,129.25 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.19 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.64 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 3.52% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/24/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.88
Price/Cash Flow: -
Price / Sales: 8.52
EPS Growth
vs. Year Ago Period: -27.00%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -45.83%
vs. Previous Quarter: -83.75%
ROE
09/30/25 - -68.17
06/30/25 - -55.96
03/31/25 - -70.58
ROA
09/30/25 - -31.32
06/30/25 - -25.73
03/31/25 - -32.97
Current Ratio
09/30/25 - 3.65
06/30/25 - 4.50
03/31/25 - 5.37
Quick Ratio
09/30/25 - -
06/30/25 - 4.50
03/31/25 - 5.37
Operating Margin
09/30/25 - -136.40
06/30/25 - -109.56
03/31/25 - -258.94
Net Margin
09/30/25 - -136.40
06/30/25 - -109.56
03/31/25 - -258.94
Pre-Tax Margin
09/30/25 - -136.00
06/30/25 - -109.19
03/31/25 - -258.28
Book Value
09/30/25 - 4.04
06/30/25 - 5.18
03/31/25 - 5.01
Inventory Turnover
09/30/25 - -
06/30/25 - -
03/31/25 - -
Debt-to-Equity
09/30/25 - 0.22
06/30/25 - 0.18
03/31/25 - 0.09
Debt-to-Capital
09/30/25 - 18.35
06/30/25 - 15.02
03/31/25 - 8.29
 

Powered by Zacks Investment Research ©